Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron

TOKYO, December 18, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Eli Lilly and Company (hereafter “Eli Lilly”, NYSE: LLY) issued a press release on December 18, 2025 (local time) regarding topline Phase 3 results from ATTAIN-MAINTAIN trial of orforglipron. Orforglipron was discovered by Chugai, and Eli Lilly holds its exclusive development and commercialization rights.

The following are the key points from Eli Lilly's news release.

• In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound
• Participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average
• Lilly has submitted orforglipron to the U.S. Food and Drug Administration for the treatment of obesity 

For the full text of Eli Lilly's news release, please refer to the Latest News via the following link:
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
https://investor.lilly.com/

This announcement is not expected to have an impact on Chugai's consolidated financial forecast for the fiscal year ending December 2025, which was announced on January 30, 2025.